Results 171 to 180 of about 5,062,336 (201)
Some of the next articles are maybe not open access.
Clinical Nuclear Medicine, 2018
Purpose The BRAFV600E mutation is the most common and specific oncogenic event in papillary thyroid carcinoma (PTC). However, its role in radioiodine therapy decision making has yet to be established.
G. Shen +4 more
semanticscholar +1 more source
Purpose The BRAFV600E mutation is the most common and specific oncogenic event in papillary thyroid carcinoma (PTC). However, its role in radioiodine therapy decision making has yet to be established.
G. Shen +4 more
semanticscholar +1 more source
Radioiodine Therapy of Thyroid Cancer
Nuclear Medicine Therapy, 2019F. Verburg
semanticscholar +1 more source
Journal of Small Animal Practice, 2017
M. Peterson, R. Nichols, M. Rishniw
semanticscholar +1 more source
M. Peterson, R. Nichols, M. Rishniw
semanticscholar +1 more source
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Ca-A Cancer Journal for Clinicians, 2021Kyle Wang
exaly
Journal of Clinical Endocrinology and Metabolism, 2006
C. Durante +10 more
semanticscholar +1 more source
C. Durante +10 more
semanticscholar +1 more source

